The Molecular Screening and Therapeutics in Leukaemia and Lymphoma Study in participants with haematological malignancies

This study aims to evaluate the feasibility and benefits of molecular screening in participants with haematological malignancies. Who is it for? You may be eligible for this study if you are: - aged 18 years and older - have pathologically confirmed blood cancer at diagnosis or relapsed/refractory disease - have sufficient and accessible tissue for molecular screening - ECOG performance status 0, 1 or 2. Study details If a patient is suitable for the MoST-LLy study, their blood cancer is tested for genetic biomarkers that may guide future treatment/s. This process is called molecular screening or genetic panel testing. After a patient’s blood cancer is tested, a report is sent to the referring haematologist with information on (i) Any genetic biomarkers that were identified in the blood cancer and (ii) The types of treatment/s or clinical trials/s that may be suitable (if any are found). The intervention and results of the screening will be assessed for biomarker identification, treatment recommendations, patient and treatment metrics and clinical outcomes. It is hoped that this research project will contribute to a better understanding of blood cancers and blood cancer genomics that may help people with blood cancer in the future. The results will aim to show genetic screening is important to expedite translation of discovery into treatment options and ultimately better outcomes for blood cancer patients.